H
Hanerxi Medical
Hanerxi develops adjustable precision pen injectors for drug delivery, specifically designed for managing chronic conditions and diseases
About Hanerxi Medical
Hanerxi Medical, officially Suzhou Hanerxi Medical Device Development Co., Ltd., was established in 2014 and is headquartered in Suzhou, China. The company operates in the therapeutic devices industry, focusing on the development and manufacturing of injector pens for medical use. Hanerxi positions itself as a research and development-driven enterprise, holding independent intellectual property rights for its injection pen technology in China.
The company's product portfolio is designed to facilitate the self-administration of drugs for chronic diseases, aiming to provide patients with safer and more convenient treatment options. Hanerxi has developed 25 different products, including both reusable and disposable pen injectors. These devices are compatible with a wide range of biologic preparations packaged in cartridge bottles or pre-filled syringes. Specific applications include injectors for Insulin, GLP-1, Liraglutide, Semaglutide, growth hormone, interferon, and Gonal-F. The business model centers on the research, development, marketing, and distribution of these injection pens. Over the years, the company has secured funding from investors such as Fuzhe Capital, Herui Venture Capital, and Zhejiang State-Owned Capital Operation.
To support its growth, Hanerxi has expanded its operational footprint significantly. In 2019, it established a wholly-owned subsidiary in Kunshan, which serves as a pilot and small-scale production center, featuring China's first fully automated injection pen production and testing line with a reported annual capacity of 24 million units. A major expansion occurred in 2024 with the establishment of another subsidiary in Lishui, Zhejiang. This large-scale production facility, with a planned annual capacity of 600 million units, represents a substantial investment aimed at meeting growing demand.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2C
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2024 | $28M | $110M | Zhejiang FuZhe Capital Management | ↗ |
| SERIES AEquity / VC | Dec 2021 | $1.4M | $5.5M | Undisclosed | — |
Growth signals
Latest recorded traffic for Hanerxi Medical is 950 monthly website visits, up 120.9% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hanerxi Medical in the Suzhou Shi ecosystem
The Hanerxi Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- ZMZhejiang FuZhe Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hanerxi Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hanerxi Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










